Cap

Zacks Small Cap Analysis – TELO Continues Development of Important Trial Bulletins – Model Slux

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Prescribed drugs (NASDAQ:TELO) is a preclinical stage biopharmaceutical firm growing a product designed to reverse organic getting older and degenerative ailments. Beforehand reported preclinical exams have proven proof that Telomir-1, the corporate’s major remedy, can lengthen telomeres and preliminary animal testing illustrates the … Read more

Zacks Small Cap Analysis – GRCE: Progress Report – Model Slux

by
Zacks Small Cap Analysis – GRCE: Progress Report – Model Slux

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) will quickly submit its new drug software (NDA) to the FDA, which we anticipate within the subsequent few weeks. The corporate just lately held a pre-NDA assembly with the FDA and got here away feeling carefully aligned with the company … Read more

Zacks Small Cap Analysis – QSG F3Q25 Earnings Assessment: EPS Miss on Decrease Revenues/Working Revenue; Unlocking a New Progress Lever – Model Slux

by

By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 6/6/25, QuantaSing (NASDAQ:QSG) reported F3Q25 (Mar) earnings outcomes. On a GAAP foundation, QSG reported internet earnings of $5.7 million for F3Q25, or $0.10 per ADS. That mentioned, excluding share-based compensation bills, adjusted EPS got here in at $0.11, or beneath our estimate … Read more

Zacks Small Cap Analysis – EVAX: Grant Illustrates Perception in Know-how – Model Slux

by

By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a scientific stage firm that’s making AI helpful within the present atmosphere by utilizing the expertise to develop new cancer-fighting vaccines. The corporate notes that it has demonstrated that it could establish, by means of the corporate’s AI fashions, novel targets … Read more

Zacks Small Cap Analysis – PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Via Scientific Trials to Enhance Surgical Outcomes, Improve Remedy Efficacy, Reduce Facet Results – Model Slux

by
Zacks Small Cap Analysis – PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Via Scientific Trials to Enhance Surgical Outcomes, Improve Remedy Efficacy, Reduce Facet Results – Model Slux

By M. Marin NASDAQ:PYPD Revolutionary Drug Supply Platform (PLEX Know-how) PolyPid Ltd. (NASDAQ:PYPD) is a late medical stage biopharma firm centered on creating domestically administered, prolonged-release therapeutics utilizing its proprietary Polymer-Lipid Encapsulation matriX (PLEX) know-how, which permits the managed supply of medicines straight on the surgical web site over prolonged durations starting from days to … Read more

x